Abstracts by keywords: claims data
To date, there are only a few studies in Germany that examine the reality of iron deficiency/anemia treatment for tumor patients who are undergoing chemotherapy. As part of a European prospective observational study, a prevalence of anemia of 40% (at the start of the study) and 67% (during the course of the study) was measured in over 15,000 tumor patients in 2001/02. In addition, the proportion of patients with anemia therapy and the distribution of the different therapy options were recorded. Of these patients, almost 40% were treated with antianemic preparations, with ESA having the highest proportion among the treatment options (Ludwig et al. 2004). In addition, Steinmetz and colleagues (2016) collected data from almost 1,000 cancer patients in Germany regarding demographic and disease-specific characteristics as well as the distribution of antianemic treatment options. It was found that the majority of patients received blood transfusions to treat the anemia and that both ESA and IV iron played a rather minor role in the treatment. The aim of this cohort study is therefore to investigate the care situation of patients with tumor disease and iron deficiency/anemia therapy. In order to better understand the reality of care in Bavaria (1/7 of those insured by statutory health insurance (GKV) in Germany), patient characteristics and disease-specific therapy options were analyzed using diagnostic and billing data as part of a PHARAO project run by the Bavarian Association of Statutory Health Insurance Physicians (KVB). analyzed.
04.04.2019
Lung cancer is one of the most common tumor diseases and the most common cause of cancer death in Germany.1,2 Only about 1/3 of non-small cell lung carcinomas (NSCLC), which is present in 80% of all lung cancer cases, is operable when initially diagnosed.3 For patients with advanced or In NSCLC that cannot be treated curatively, only marginal improvements in response and survival have been achieved over decades with systemic therapy, usually with chemotherapy. With the discovery that the growth of some tumors is driven by an activating mutation of the tyrosine kinase and that these can be specifically inhibited, there have been significant advances in the treatment of lung cancer in the field of precision medicine, also known as personalized medicine, for around ten years .4 This means that around 30% of all NSCLC patients in advanced stages can now be treated in a personalized or targeted manner.4 In randomized studies, patients with NSCLC and mutations in the EGF receptors have higher response rates, longer progression-free survival and lower rates when treated with a TKI Side effects compared to cytotoxic chemotherapy.8 In addition, several treatment cohorts worldwide have shown an improvement in overall survival with personalized medicine for lung cancer.9 The patients recorded in the Cologne Network for Genomic Medicine (NGM) showed lung cancer compared to a historical control group with the relevant driver mutations a significant increase in overall survival of a median of 21.9 months in EGFR-positive and 12 months in ALK-positive NSCLC patients.10
04.04.2019
According to calculations by the World Health Organization (WHO), around 10% of children worldwide and around 6% of children in Europe are born prematurely (1). Births before the 37th week of pregnancy (week of pregnancy) are defined as premature births (2). In neonatal intensive care, preterm birth is still the most common cause of neonatal and early childhood morbidity and mortality and can lead to lifelong health and psychosocial impairments (3–5). The health economic consequences associated with premature birth are also considerable (6). There are many factors that can lead to premature birth. Previous abortions and premature births, the increasing age of first-time mothers and the higher incidence of multiple pregnancies due to previous fertility treatments can cause premature births (4,7,8). Maternal infections, such as bacterial vaginosis, have also been identified as a cause of premature births, although the pathophysiological connections are not yet fully understood (9,2,10,11). The early detection and treatment of bacterial vaginosis can be implemented and carried out relatively easily and therefore represents a promising possibility to prevent preterm birth and to reduce the resulting health and psychosocial consequences.
24.07.2017
Heart failure is one of the most medically and health-economically important diseases in Germany (Neumann et al. 2009; Gensichen et al. 2004; Zugck et al. 2010; Willich et al. 2013; Buhr et al. 2007). The prevalence of heart failure is strongly age-dependent, so it can be assumed that the costs for diagnosis and treatment of heart failure will increase in the coming years in view of the aging German population. A large part of the treatment costs for heart failure arise in the inpatient area (Zugck et al. 2010). Against this background, effective integrated care programs have the potential to improve the care of heart failure patients and at the same time prevent decompensations, which are particularly often treated in the inpatient setting. Effective new care programs make it possible to optimize treatment processes, especially in the outpatient area, and to actively involve patients in the treatment concept (Buhr et al. 2007).
29.11.2016
Providing Multiple Sclerosis Patients with Ready-to-Use Cannabis Medicinal Products. Spasticity is one of the most significant symptoms of multiple sclerosis (MS), which is associated with significant limitations in daily life. Cannabis has been discussed for some time as a possible option for inadequately treatable spasticity, but for a long time, there were no approved preparations in Germany. This changed in the middle of last year, when […]